atai Life Sciences

Canaccord Genuity Acted as Co-Manager to atai Life Sciences on its Public Offering of $149.5 Million

Canaccord Genuity is pleased to announce its client atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, closed its public offering resulting in gross proceeds of approximately $149.5 million, before deducting underwriting discounts and other expenses. 

atai sold 27,283,750 shares of its common stock, inclusive of the closing of the underwriters’ option in full to purchase an additional 3,558,750 common shares at the public offering price of $5.48 per share following the exercise by the underwriters of their option.

Canaccord Genuity acted as co-manager for the offering.

atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Its pipeline of psychedelic-based therapies includes BPL-003 (intranasal mebufotenin benzoate) for treatment-resistant depression (TRD), which is being advanced through a strategic investment and planned strategic combination with Beckley Psytech Limited; VLS-01 (buccal film DMT) also for TRD; and EMP-01 (oral R-MDMA) for social anxiety disorder. All three programs are in Phase 2 clinical development. atai is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD and opioid use disorder. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. atai’s headquarters are in Amstelveen, Netherlands.